Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

A Diagnostic Ceiling for Exome Sequencing in Cerebellar Ataxia and Related Neurological Disorders.

Ngo KJ, Rexach JE, Lee H, Petty LE, Perlman S, Valera JM, Deignan JL, Mao Y, Aker M, Posey JE, Jhangiani SN, Coban-Akdemir ZH, Boerwinkle E, Muzny D, Nelson AB, Hassin-Baer S, Poke G, Neas K, Geschwind MD, Grody WW, Gibbs R, Geschwind DH, Lupski JR, Below JE, Nelson SF, Fogel BL.

Hum Mutat. 2019 Nov 6. doi: 10.1002/humu.23946. [Epub ahead of print]

PMID:
31692161
2.

Genetic, structural and functional evidence link TMEM175 to synucleinopathies.

Krohn L, Öztürk TN, Vanderperre B, Ouled Amar Bencheikh B, Ruskey JA, Laurent SB, Spiegelman D, Postuma RB, Arnulf I, Hu MTM, Dauvilliers Y, Högl B, Stefani A, Monaca CC, Plazzi G, Antelmi E, Ferini-Strambi L, Heidbreder A, Rudakou U, Cochen De Cock V, Young P, Wolf P, Oliva P, Zhang XK, Greenbaum L, Liong C, Gagnon JF, Desautels A, Hassin-Baer S, Montplaisir JY, Dupré N, Rouleau GA, Fon EA, Trempe JF, Lamoureux G, Alcalay RN, Gan-Or Z.

Ann Neurol. 2019 Oct 28. doi: 10.1002/ana.25629. [Epub ahead of print]

PMID:
31658403
3.

Excessive phase synchronization in cortical activation during locomotion in persons with Parkinson's disease.

Miron-Shahar Y, Kantelhardt JW, Grinberg A, Hassin-Baer S, Blatt I, Inzelberg R, Plotnik M.

Parkinsonism Relat Disord. 2019 Aug;65:210-216. doi: 10.1016/j.parkreldis.2019.05.030. Epub 2019 May 22.

PMID:
31383631
4.

Coupling Between Leg Muscle Activation and EEG During Normal Walking, Intentional Stops, and Freezing of Gait in Parkinson's Disease.

Günther M, Bartsch RP, Miron-Shahar Y, Hassin-Baer S, Inzelberg R, Kurths J, Plotnik M, Kantelhardt JW.

Front Physiol. 2019 Jul 12;10:870. doi: 10.3389/fphys.2019.00870. eCollection 2019.

5.

Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.

Agalliu I, Ortega RA, Luciano MS, Mirelman A, Pont-Sunyer C, Brockmann K, Vilas D, Tolosa E, Berg D, Warø B, Glickman A, Raymond D, Inzelberg R, Ruiz-Martinez J, Mondragon E, Friedman E, Hassin-Baer S, Alcalay RN, Mejia-Santana H, Aasly J, Foroud T, Marder K, Giladi N, Bressman S, Saunders-Pullman R.

Mov Disord. 2019 Sep;34(9):1392-1398. doi: 10.1002/mds.27807. Epub 2019 Jul 26.

6.

The spectrum of tremor among carriers of the FMR1 premutation with or without the fragile X-associated tremor/ataxia syndrome (FXTAS).

Fay-Karmon T, Hassin-Baer S.

Parkinsonism Relat Disord. 2019 Aug;65:32-38. doi: 10.1016/j.parkreldis.2019.05.010. Epub 2019 May 7. Review.

PMID:
31126791
7.

Catastrophizing mediates the relationship between non-motor symptoms and quality of life in Parkinson's disease.

Lerman SF, Bronner G, Cohen OS, Elincx-Benizri S, Strauss H, Yahalom G, Hassin-Baer S.

Disabil Health J. 2019 Oct;12(4):673-678. doi: 10.1016/j.dhjo.2019.03.006. Epub 2019 Mar 19.

PMID:
30928237
8.

Decreasing battery life in subthalamic deep brain stimulation for Parkinson's disease with repeated replacements: Just a matter of energy delivered?

Israeli-Korn SD, Fay-Karmon T, Tessler S, Yahalom G, Benizri S, Strauss H, Zibly Z, Spiegelmann R, Hassin-Baer S.

Brain Stimul. 2019 Jul - Aug;12(4):845-850. doi: 10.1016/j.brs.2019.02.008. Epub 2019 Feb 22.

PMID:
30876884
9.

SMPD1 mutations, activity, and α-synuclein accumulation in Parkinson's disease.

Alcalay RN, Mallett V, Vanderperre B, Tavassoly O, Dauvilliers Y, Wu RYJ, Ruskey JA, Leblond CS, Ambalavanan A, Laurent SB, Spiegelman D, Dionne-Laporte A, Liong C, Levy OA, Fahn S, Waters C, Kuo SH, Chung WK, Ford B, Marder KS, Kang UJ, Hassin-Baer S, Greenbaum L, Trempe JF, Wolf P, Oliva P, Zhang XK, Clark LN, Langlois M, Dion PA, Fon EA, Dupre N, Rouleau GA, Gan-Or Z.

Mov Disord. 2019 Apr;34(4):526-535. doi: 10.1002/mds.27642. Epub 2019 Feb 20.

PMID:
30788890
10.

Ultrasound-Guided Botulinum Toxin Injections into the Salivary Glands for the Treatment of Drooling.

Abboud WA, Nadel S, Hassin-Baer S, Arad A, Dobriyan A, Yahalom R.

Isr Med Assoc J. 2019 Feb;21(2):116-119.

11.

Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations.

Yahalom G, Greenbaum L, Israeli-Korn S, Fay-Karmon T, Livneh V, Ruskey JA, Roncière L, Alam A, Gan-Or Z, Hassin-Baer S.

Parkinsonism Relat Disord. 2019 May;62:179-184. doi: 10.1016/j.parkreldis.2018.12.014. Epub 2018 Dec 13.

PMID:
30573413
12.

Frequency of Loss of Function Variants in LRRK2 in Parkinson Disease.

Blauwendraat C, Reed X, Kia DA, Gan-Or Z, Lesage S, Pihlstrøm L, Guerreiro R, Gibbs JR, Sabir M, Ahmed S, Ding J, Alcalay RN, Hassin-Baer S, Pittman AM, Brooks J, Edsall C, Hernandez DG, Chung SJ, Goldwurm S, Toft M, Schulte C, Bras J, Wood NW, Brice A, Morris HR, Scholz SW, Nalls MA, Singleton AB, Cookson MR; COURAGE-PD (Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson’s Disease) Consortium, the French Parkinson’s Disease Consortium, and the International Parkinson’s Disease Genomics Consortium (IPDGC).

JAMA Neurol. 2018 Nov 1;75(11):1416-1422. doi: 10.1001/jamaneurol.2018.1885.

13.

Acquired premature ejaculation in Parkinson's disease and possible mechanisms.

Bronner G, Israeli-Korn S, Hassin-Baer S, Yahalom G.

Int J Impot Res. 2018 Aug;30(4):153-157. doi: 10.1038/s41443-018-0034-6. Epub 2018 Jun 1.

PMID:
29855551
14.

Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease.

Ruskey JA, Greenbaum L, Roncière L, Alam A, Spiegelman D, Liong C, Levy OA, Waters C, Fahn S, Marder KS, Chung W, Yahalom G, Israeli-Korn S, Livneh V, Fay-Karmon T, Alcalay RN, Hassin-Baer S, Gan-Or Z.

Eur J Med Genet. 2019 Jan;62(1):65-69. doi: 10.1016/j.ejmg.2018.05.005. Epub 2018 May 26.

PMID:
29842932
15.

Anodic versus cathodic neurostimulation of the subthalamic nucleus: A randomized-controlled study of acute clinical effects.

Kirsch AD, Hassin-Baer S, Matthies C, Volkmann J, Steigerwald F.

Parkinsonism Relat Disord. 2018 Oct;55:61-67. doi: 10.1016/j.parkreldis.2018.05.015. Epub 2018 May 16.

16.

[FMR1 PREMUTATION CARRIERS - ARE THEY REALLY ASYMPTOMATIC?]

Elizur S, Berkenstadt M, Ries-Levavi L, Gruber N, Pinhas-Hamiel O, Hassin-Baer S, Raas-Rothschild A, Raanani H, Cukierman-Yaffe T, Orvieto R, Cohen Y, Gabis L.

Harefuah. 2018 Apr;157(4):241-244. Review. Hebrew.

PMID:
29688643
17.

Expanding the global prevalence of spinocerebellar ataxia type 42.

Ngo K, Aker M, Petty LE, Chen J, Cavalcanti F, Nelson AB, Hassin-Baer S, Geschwind MD, Perlman S, Italiano D, Laganà A, Cavallaro S, Coppola G, Below JE, Fogel BL.

Neurol Genet. 2018 Apr 5;4(3):e232. doi: 10.1212/NXG.0000000000000232. eCollection 2018 Jun. No abstract available. Erratum in: Neurol Genet. 2018 May 18;4(3):e238.

18.

Evolution of echovirus 11 in a chronically infected immunodeficient patient.

Laassri M, Zagorodnyaya T, Hassin-Baer S, Handsher R, Sofer D, Weil M, Karagiannis K, Simonyan V, Chumakov K, Shulman L.

PLoS Pathog. 2018 Mar 19;14(3):e1006943. doi: 10.1371/journal.ppat.1006943. eCollection 2018 Mar.

19.

Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's disease.

Blauwendraat C, Kia DA, Pihlstrøm L, Gan-Or Z, Lesage S, Gibbs JR, Ding J, Alcalay RN, Hassin-Baer S, Pittman AM, Brooks J, Edsall C, Chung SJ, Goldwurm S, Toft M, Schulte C; International Parkinson's Disease Genomics Consortium (IPDGC), COURAGE-PD Consortium, Hernandez D, Singleton AB, Nalls MA, Brice A, Scholz SW, Wood NW.

Neurobiol Aging. 2018 Apr;64:159.e5-159.e8. doi: 10.1016/j.neurobiolaging.2017.12.012. Epub 2017 Dec 20.

20.

Repetitive Deep TMS for Parkinson Disease: A 3-Month Double-Blind, Randomized Sham-Controlled Study.

Cohen OS, Rigbi A, Yahalom G, Warman-Alaluf N, Nitsan Z, Zangen A, Hassin-Baer S.

J Clin Neurophysiol. 2018 Mar;35(2):159-165. doi: 10.1097/WNP.0000000000000455.

PMID:
29373395
21.

Localized myofascial pain responds better than referring myofascial pain to botulinum toxin injections.

Abboud WA, Hassin-Baer S, Joachim M, Givol N, Yahalom R.

Int J Oral Maxillofac Surg. 2017 Nov;46(11):1417-1423. doi: 10.1016/j.ijom.2017.04.020. Epub 2017 May 15.

PMID:
28521968
22.

The impact of early versus late levodopa administration.

Yahalom G, Cohen OS, Warmann-Alaluf N, Shabat C, Strauss H, Elincx-Benizri S, Israeli-Korn S, Stein E, Greenbaum L, Hassin-Baer S.

J Neural Transm (Vienna). 2017 Apr;124(4):471-476. doi: 10.1007/s00702-016-1669-4. Epub 2016 Dec 21.

PMID:
28004202
23.

Sexual Preoccupation Behavior in Parkinson's Disease.

Bronner G, Hassin-Baer S, Gurevich T.

J Parkinsons Dis. 2017;7(1):175-182. doi: 10.3233/JPD-160926. Review.

PMID:
27802244
24.

Clinical Experience With Deferiprone Treatment for Friedreich Ataxia.

Elincx-Benizri S, Glik A, Merkel D, Arad M, Freimark D, Kozlova E, Cabantchik I, Hassin-Baer S.

J Child Neurol. 2016 Jul;31(8):1036-40. doi: 10.1177/0883073816636087. Epub 2016 Mar 29.

PMID:
27029487
25.

Decreased Anti-Parkinson's Therapy during Hospitalization due to Infectious Diseases is Associated with Worse Prognosis.

Segal O, Hassin-Baer S, Kliers I, Gringouz I, Dagan A, Cohen S, Segal G.

CNS Neurosci Ther. 2016 May;22(5):423-5. doi: 10.1111/cns.12545. Epub 2016 Mar 25. No abstract available.

26.

Repetitive deep transcranial magnetic stimulation for motor symptoms in Parkinson's disease: A feasibility study.

Cohen OS, Orlev Y, Yahalom G, Amiaz R, Nitsan Z, Ephraty L, Rigbi A, Shabat C, Zangen A, Hassin-Baer S.

Clin Neurol Neurosurg. 2016 Jan;140:73-8. doi: 10.1016/j.clineuro.2015.11.017. Epub 2015 Nov 24.

PMID:
26658034
27.

Can the disease course in Parkinson's disease be slowed?

Korczyn AD, Hassin-Baer S.

BMC Med. 2015 Dec 10;13:295. doi: 10.1186/s12916-015-0534-x.

28.

Low Norton Scale Score Predicts Worse Outcomes for Parkinson's Disease Patients Hospitalized Due to Infection.

Segal O, Hassin-Baer S, Kliers I, Cale' KS, Segal G.

Gerontol Geriatr Med. 2015 Sep 23;1:2333721415608139. doi: 10.1177/2333721415608139. eCollection 2015 Jan-Dec.

29.

Sexuality in patients with Parkinson's disease, Alzheimer's disease, and other dementias.

Bronner G, Aharon-Peretz J, Hassin-Baer S.

Handb Clin Neurol. 2015;130:297-323. doi: 10.1016/B978-0-444-63247-0.00017-1. Review.

PMID:
26003251
30.

Decreased dopaminergic treatment of hospitalized Parkinson's disease patients during infectious diseases is associated with poor outcomes.

Segal O, Hassin-Baer S, Rosman M, Segal G.

J Clin Neurosci. 2015 Aug;22(8):1272-4. doi: 10.1016/j.jocn.2015.02.010. Epub 2015 Apr 22.

PMID:
25911502
31.

The neuropsychological profile of patients with 3-methylglutaconic aciduria type III, Costeff syndrome.

Sofer S, Schweiger A, Blumkin L, Yahalom G, Anikster Y, Lev D, Ben-Zeev B, Lerman-Sagie T, Hassin-Baer S.

Am J Med Genet B Neuropsychiatr Genet. 2015 Apr;168B(3):197-203. doi: 10.1002/ajmg.b.32296. Epub 2015 Feb 5.

PMID:
25657044
32.

Exploring determinants of progression in Parkinson's disease. Is there a difference among Jewish ethnic groups?

Orlev Y, Yahalom G, Cohen OS, Elincx-Benizri S, Kozlova E, Inzelberg R, Goldbourt U, Hassin-Baer S.

Parkinsonism Relat Disord. 2015 Mar;21(3):184-8. doi: 10.1016/j.parkreldis.2014.10.009. Epub 2014 Oct 18.

PMID:
25550275
33.

Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.

Agalliu I, San Luciano M, Mirelman A, Giladi N, Waro B, Aasly J, Inzelberg R, Hassin-Baer S, Friedman E, Ruiz-Martinez J, Marti-Masso JF, Orr-Urtreger A, Bressman S, Saunders-Pullman R.

JAMA Neurol. 2015 Jan;72(1):58-65. doi: 10.1001/jamaneurol.2014.1973.

34.

Genetic movement disorders in patients of Jewish ancestry.

Inzelberg R, Hassin-Baer S, Jankovic J.

JAMA Neurol. 2014 Dec;71(12):1567-72. doi: 10.1001/jamaneurol.2014.1364. Review.

PMID:
25347348
35.

The melanocortin 1 receptor (Mc1r) variants do not account for the co-occurrence of Parkinson's disease and malignant melanoma.

Elincx-Benizri S, Inzelberg R, Greenbaum L, Cohen OS, Yahalom G, Laitman Y, Djaldetti R, Orlev Y, Scope A, Azizi E, Friedman E, Hassin-Baer S.

J Mol Neurosci. 2014 Dec;54(4):820-5. doi: 10.1007/s12031-014-0425-1. Epub 2014 Oct 5.

PMID:
25284244
36.

Costeff syndrome: clinical features and natural history.

Yahalom G, Anikster Y, Huna-Baron R, Hoffmann C, Blumkin L, Lev D, Tsabari R, Nitsan Z, Lerman SF, Ben-Zeev B, Pode-Shakked B, Sofer S, Schweiger A, Lerman-Sagie T, Hassin-Baer S.

J Neurol. 2014 Dec;261(12):2275-82. doi: 10.1007/s00415-014-7481-x. Epub 2014 Sep 9.

PMID:
25201222
37.

Correlates of quality of sexual life in male and female patients with Parkinson disease and their partners.

Bronner G, Cohen OS, Yahalom G, Kozlova E, Orlev Y, Molshatzki N, Strauss H, Hassin-Baer S.

Parkinsonism Relat Disord. 2014 Oct;20(10):1085-8. doi: 10.1016/j.parkreldis.2014.07.003. Epub 2014 Jul 12.

PMID:
25131540
38.

Cardiac stress test is normal in pre-motor Parkinson's disease.

Yahalom G, Maor E, Hassin-Baer S, Segev S, Sidi Y, Kivity S.

Mov Disord. 2014 Aug;29(9):1158-62. doi: 10.1002/mds.25943. Epub 2014 Jun 20.

PMID:
24954917
39.

Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation.

Yahalom G, Orlev Y, Cohen OS, Kozlova E, Friedman E, Inzelberg R, Hassin-Baer S.

Mov Disord. 2014 Jul;29(8):1057-60. doi: 10.1002/mds.25931. Epub 2014 Jun 5.

PMID:
24903616
40.

Enhanced creative thinking under dopaminergic therapy in Parkinson disease.

Faust-Socher A, Kenett YN, Cohen OS, Hassin-Baer S, Inzelberg R.

Ann Neurol. 2014 Jun;75(6):935-42. doi: 10.1002/ana.24181. Epub 2014 Jun 10. Erratum in: Ann Neurol. 2019 Mar;85(3):E1.

PMID:
24816898
41.

Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.

Kaplan N, Vituri A, Korczyn AD, Cohen OS, Inzelberg R, Yahalom G, Kozlova E, Milgrom R, Laitman Y, Friedman E, Rosset S, Hassin-Baer S.

J Mol Neurosci. 2014 Jun;53(2):183-8. doi: 10.1007/s12031-014-0276-9. Epub 2014 Mar 15.

PMID:
24633632
42.

A deficit in optimizing task solution but robust and well-retained speed and accuracy gains in complex skill acquisition in Parkinson׳s disease: multi-session training on the Tower of Hanoi Puzzle.

Vakil E, Hassin-Baer S, Karni A.

Neuropsychologia. 2014 May;57:12-9. doi: 10.1016/j.neuropsychologia.2014.02.005. Epub 2014 Feb 11.

PMID:
24530238
43.

Asymmetric dopamine loss differentially affects effort to maximize gain or minimize loss.

Porat O, Hassin-Baer S, Cohen OS, Markus A, Tomer R.

Cortex. 2014 Feb;51:82-91. doi: 10.1016/j.cortex.2013.10.004. Epub 2013 Oct 30.

PMID:
24267688
44.

The LRRK2 G2019S mutation status does not affect the outcome of subthalamic stimulation in patients with Parkinson's disease.

Greenbaum L, Israeli-Korn SD, Cohen OS, Elincx-Benizri S, Yahalom G, Kozlova E, Strauss H, Molshatzki N, Inzelberg R, Spiegelmann R, Israel Z, Hassin-Baer S.

Parkinsonism Relat Disord. 2013 Nov;19(11):1053-6. doi: 10.1016/j.parkreldis.2013.07.005. Epub 2013 Aug 6.

PMID:
23932063
45.

Subthalamic nucleus deep brain stimulation does not improve visuo-motor impairment in Parkinson's disease.

Israeli-Korn SD, Hocherman S, Hassin-Baer S, Cohen OS, Inzelberg R.

PLoS One. 2013 Jun 11;8(6):e65270. doi: 10.1371/journal.pone.0065270. Print 2013.

46.

Parkinson's disease genes do not segregate with breast cancer genes' loci.

Kravitz E, Laitman Y, Hassin-Baer S, Inzelberg R, Friedman E.

Cancer Epidemiol Biomarkers Prev. 2013 Aug;22(8):1464-72. doi: 10.1158/1055-9965.EPI-13-0472. Epub 2013 Jun 13.

47.

Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis.

Yahalom G, Tsabari R, Molshatzki N, Ephraty L, Cohen H, Hassin-Baer S.

Clin Neuropharmacol. 2013 May-Jun;36(3):78-83. doi: 10.1097/WNF.0b013e318288076a.

PMID:
23673909
48.

Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study.

Greenbaum L, Goldwurm S, Zozulinsky P, Lifschytz T, Cohen OS, Yahalom G, Cilia R, Tesei S, Asselta R, Inzelberg R, Kohn Y, Hassin-Baer S, Lerer B.

J Mol Neurosci. 2013 Oct;51(2):380-8. doi: 10.1007/s12031-013-0020-x. Epub 2013 May 12.

PMID:
23666822
49.

Analysis of LMNB1 duplications in autosomal dominant leukodystrophy provides insights into duplication mechanisms and allele-specific expression.

Giorgio E, Rolyan H, Kropp L, Chakka AB, Yatsenko S, Di Gregorio E, Lacerenza D, Vaula G, Talarico F, Mandich P, Toro C, Pierre EE, Labauge P, Capellari S, Cortelli P, Vairo FP, Miguel D, Stubbolo D, Marques LC, Gahl W, Boespflug-Tanguy O, Melberg A, Hassin-Baer S, Cohen OS, Pjontek R, Grau A, Klopstock T, Fogel B, Meijer I, Rouleau G, Bouchard JP, Ganapathiraju M, Vanderver A, Dahl N, Hobson G, Brusco A, Brussino A, Padiath QS.

Hum Mutat. 2013 Aug;34(8):1160-71. doi: 10.1002/humu.22348. Epub 2013 May 28. Erratum in: Hum Mutat. 2014 Jan;35(1):149.

50.

Effects of asymmetric dopamine depletion on sensitivity to rewarding and aversive stimuli in Parkinson's disease.

Maril S, Hassin-Baer S, Cohen OS, Tomer R.

Neuropsychologia. 2013 Apr;51(5):818-24. doi: 10.1016/j.neuropsychologia.2013.02.003. Epub 2013 Feb 17.

PMID:
23422331

Supplemental Content

Loading ...
Support Center